CHICAGO – In-hospital initiation of sacubitril/valsartan safely and significantly reduced heart failure rehospitalizations in the next 8 weeks.
The large outcomes trial didn’t show a benefit in major adverse cardiovascular events.
The agency found the lowest bleeding risk with apixaban, but cites lack of head-to-head trials as a limitation in evaluating DOACs.
Despite some big wins, it wasn't a clean sweep for Medicaid in the Nov. 6, elections.
News from the FDA/CDC
Prevalence dropped to 14% among adults in 2017, but control strategies need to “address the diversity of tobacco products.”
Plan selections for the first week were down, compared with last year.
Patients with decision-making capacity or their legally defined surrogates have the right to refuse or request withdrawal of pacemaker therapy.
ORLANDO – “When you have these devices that have flavors like gummy bear and cotton candy and bubblegum, you are marketing to children.”
From the Journals
Disagreement over the ACC/AHA blood pressure guidelines threatens to distract from their potential benefits.